Search Results for: -trrxht.html

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. “Opening enrollment on our first

CHICAGO, IL and FORT WORTH, TX, January 15, 2018 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical study of 9-ING-41, Actuate’s lead agent – a proprietary GSK-3β inhibitor. This initial IND

CHICAGO, IL and FORT WORTH, TX, October 26, 2017 – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to 9-ING-41, Actuate’s lead clinical development candidate, for the treatment of neuroblastoma. The Rare Pediatric Disease Designation of 9-ING for the